Cellectis (CLLS) EBITDA Margin Growth (3y) (2018 - 2026)
Powered by 
Analysis
Cellectis (CLLS) EBITDA Margin Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7,045.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1,934.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7,261.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 9,003.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -2,649.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 30,461.00 |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 1.28 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Dec 31, 2025 | -10,114.00 |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 203,243.00 |
| Mar 31, 2025 | 162,236.00 |
| Dec 31, 2024 | 33,459.00 |
| Sep 30, 2024 | 44,325.00 |
| Jun 30, 2024 | 12,186.00 |
| Mar 31, 2024 | -38,368.00 |
| Dec 31, 2023 | -1.51 Mn |
| Sep 30, 2023 | -1.29 Mn |
| Jun 30, 2023 | -1.21 Mn |
| Mar 31, 2023 | -2.01 Mn |
| Dec 31, 2022 | 83,501.00 |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | 95,938.00 |
| Mar 31, 2022 | 47,613.00 |
| Dec 31, 2021 | 278,391.00 |
| Sep 30, 2021 | 268,057.00 |